Ashley Gallagher, Associate Editor

Findings of the phase 2 cohort and the phase 1b cohort of the KRYSTAL-1 study are being presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Efanesoctocog alfa is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeding with a once-weekly prophylactic dosing.

With a median follow-up of 90 months, individuals receiving palbociclib in combination with letrozole had numerically longer OS compared to placebo, but it was not deemed statistically significant.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Ibrutinib plus bendamustine-rituximab and rituximab maintenance was found to lower the risk of disease progression or death by 25% compared with placebo in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Dupilumab is under clinical development, and the efficacy and safety have not been fully evaluated by any regulatory authorities.

The drug is a treatment for individuals who are healing all grades of erosive esophagitis, as a relief of heartburn, and as maintenance of healing all grades of EE and relief of heartburn.

Analysis shows that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect the treatment benefit with alpelisib (Piqray) combined with fulvestrant in individuals with HR+/HER2- advanced or metastatic breast cancer.

Improvement in recurrence-free survival was seen primarily in individuals with very high-risk renal cell carcinoma, whereas individuals with intermediate high-risk disease showed no improvements in survival.

The median overall survival was 66 months for individuals with hormone receptor-positive/human epidermal growth factor receptor-negative advanced or metastatic breast cancer administered at least 1 dose reduction of ribociclib (Kisqali) from the starting dose of 600 mg.

The gout medicine is a potential treatment option for individuals hospitalized for the cardiovascular condition, analysis suggests.

The findings show that at 90 days, the modified Rankin Score (mRS) had a significantly greater number of individuals with an improvement of 2 points or greater.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

Analysis also shows a reduction in the need for opiate painkillers, and there was a decrease in other cancer-related symptoms, according to results published in Frontiers in Pain Research.

The medications are linked with reduced negative emotional bias, according to new research published in Biological Psychiatry.

Analysis provides new understanding of the effect of probiotics on the tiniest of infants in the neonatal intensive care.

In ECOSPOR III, the lead therapeutic candidate incorporated itself durably and rapidly into the microbiome to prevent recurrence, the company says.

The FreeStyle Libre 3 is the most accurate 14-day continuous glucose monitor with a 7.9% overall mean absolute relative difference and readings are sent directly to a smartphone every minute.

Further sensitivity analyses to control for family alcohol consumption, family history, liver disease, and smoking, finds no convincing evidence that these factors affected the results.

Research suggests that individuals receiving a vaccine, such as ones from AstraZeneca and Johnson & Johnson, were more vulnerable to infection by new variants.

Taking multiple prescription drugs and supplements can be especially dangerous for individuals with cancer who are about to undergo therapy.

When both the clinical criteria and genetic testing were combined, 6.6 familial hypercholesterolemia cases per 1000 individuals screened were found.

Using machine learning, they find patterns in electronic health record data to help ascertain which individuals likely have the condition.

Investigators establish 2 predictive models, which had excellent performance, and included 90 children.

The approval is supported by data from a global phase 3 trial assessing the use of the drug for individuals with previously untreated IDH1-mutated acute myeloid leukemia.

The study results support a hypothesis for a differentiated mechanism from risankizumab, the company says.

Investigators suggested a new test method for the infection with ESAT6/CFP10 and to monitor the disease development and treatment with Ag85B.

But HRT is associated with positive changes to cholesterol levels, though the sample size was small, the analysis shows.

The analysis, results of which are published in The Lancer Psychiatry, also identifies genetic markers that seem to influence how quickly the body eliminates the medication from its system.

Study results also show a 50% increase in the precancerous condition, Barrett esophagus, between 2012 and 2019, in the same population.